Cochrane · systematic review · CD010893
Interventions for reducing inflammation in familial Mediterranean fever
Yin, X, Tian, F, Wu, B, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
36
current version
GRADE rated
20
No studies
16
Included studies
NR
No studies 16 · 44.4%Ungraded 0 · 0%Very low 3 · 8.3%Low 6 · 16.7%Moderate 11 · 30.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyColchicine (oral) versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attacka,b Colchicine (oral) vs placebo | RR 0.21 [0.05, 0.95] | 1 study · 10 participants | Low Downgraded: risk of bias, imprecision |
Duration of attackse,f Colchicine (oral) vs placebo | no estimate extracted | 1 study · 9 participants | Very low Downgraded: risk of bias, imprecision |
Time between attackse,f Colchicine (oral) vs placebo | no estimate extracted | 1 study · 11 participants | Very low |
Prevention of AA amyloidosis Colchicine (oral) vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions Colchicine (oral) vs placebo | no estimate extracted | 1 study · 11 participants | Very low |
Acute‐phase response Colchicine (oral) vs placebo | no estimate extracted | NR | No studies |
Rilonacept versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attacka Rilonacept vs placebo | RR 0.87 [0.59, 1.26] | 1 study · 14 participants | Moderate Downgraded: imprecision |
Duration of attacksa Rilonacept vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Time between attacksa Rilonacept vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Prevention of AA amyloidosis Rilonacept vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions Rilonacept vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Acute‐phase response Rilonacept vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
ImmunoGuard versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attacka ImmunoGuard vs placebo | no estimate extracted | NR | No studies |
Duration of attacks ImmunoGuard vs placebo | no estimate extracted | NR | No studies |
Time between attacks ImmunoGuard vs placebo | no estimate extracted | NR | No studies |
Prevention of AA amyloidosis ImmunoGuard vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions ImmunoGuard vs placebo | no estimate extracted | 1 study · 23 participants | Moderate Downgraded: imprecision |
Acute‐phase response ImmunoGuard vs placebo | no estimate extracted | 1 study · 23 participants | Moderate Downgraded: imprecision |
Anakinra versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attacka Anakinra vs placebo | RR 0.76 [0.54, 1.07] | 1 study · 25 participants | Moderate Downgraded: imprecision |
Duration of attacks Anakinra vs placebo | no estimate extracted | NR | No studies |
Time between attacks Anakinra vs placebo | no estimate extracted | NR | No studies |
Prevention of AA amyloidosis Anakinra vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions Anakinra vs placebo | RR 0.54 [0.12, 2.44] | 1 study · 25 participants | Moderate Downgraded: imprecision |
Acute‐phase response Anakinra vs placebo | no estimate extracted | 1 study · 20 participants | Moderate Downgraded: imprecision |
Canakinumab versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with colchicine‐resistant familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attacka Canakinumab vs placebo | RR 0.41 [0.26, 0.65] | 1 study · 63 participants | Moderate Downgraded: imprecision |
Duration of attacks Canakinumab vs placebo | no estimate extracted | NR | No studies |
Time between attacks Canakinumab vs placebo | no estimate extracted | NR | No studies |
Prevention of AA amyloidosis Canakinumab vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions Canakinumab vs placebo | no estimate extracted | 1 study · 63 participants | Moderate Downgraded: imprecision |
Acute‐phase response Canakinumab vs placebo | no estimate extracted | 1 study · 63 participants | Moderate Downgraded: imprecision |
Colchicine single dose versus divided dose for reducing inflammation in familial Mediterranean fever
Population: children with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attack Colchicine single dose vs divided dose | no estimate extracted | NR | No studies |
Duration of attacksa Colchicine single dose vs divided dose | no estimate extracted | 1 study · 79 participants | Moderate Downgraded: risk of bias |
Time between attacks Colchicine single dose vs divided dose | no estimate extracted | NR | No studies |
Prevention of AA amyloidosis Colchicine single dose vs divided dose | no estimate extracted | NR | No studies |
Adverse drug reactions Colchicine single dose vs divided dose | no estimate extracted | 1 study · 79 participants | Moderate Downgraded: risk of bias |
Acute‐phase response Colchicine single dose vs divided dose | no estimate extracted | 1 study · 39 participants | Low Downgraded: risk of bias, imprecision |
Colchicine (oral) versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attack1,2 Colchicine (oral) vs placebo | RR 0.21 [0.05, 0.95] | 1 study · 10 participants | Low Downgraded: risk of bias, imprecision |
Duration of attacks3,4 Colchicine (oral) vs placebo | no estimate extracted | 1 study · 9 participants | Very low Downgraded: risk of bias, imprecision |
Number of days between attacks3,4 Colchicine (oral) vs placebo | no estimate extracted | 1 study · 11 participants | Very low Downgraded: risk of bias, imprecision |
Prevention of AA amyloidosis Colchicine (oral) vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions Colchicine (oral) vs placebo | no estimate extracted | 1 study · 11 participants | Very low Downgraded: risk of bias, imprecision |
Acute phase response Colchicine (oral) vs placebo | no estimate extracted | NR | No studies |
Rilonacept versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attack1 Rilonacept vs placebo | RR 0.87 [0.59, 1.26] | 1 study · 14 participants | Moderate Downgraded: imprecision |
Duration of attacks1 Rilonacept vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Number of days between attacks1 Rilonacept vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Prevention of AA amyloidosis Rilonacept vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions Rilonacept vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Acute phase response Rilonacept vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
ImmunoGuardTM versus placebo for reducing inflammation in familial Mediterranean fever
Population: participants with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attack1 ImmunoGuardTM vs placebo | no estimate extracted | NR | No studies |
Duration of attacks1 ImmunoGuardTM vs placebo | no estimate extracted | NR | No studies |
Number of days1 between attacks ImmunoGuardTM vs placebo | no estimate extracted | NR | No studies |
Prevention of AA amyloidosis ImmunoGuardTM vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions ImmunoGuardTM vs placebo | no estimate extracted | 1 study · 23 participants | Moderate Downgraded: imprecision |
Acute phase response ImmunoGuardTM vs placebo | no estimate extracted | 1 study · 23 participants | Moderate Downgraded: imprecision |
Anakinra versus placebo for reducing inflammation in familial Mediterranean fever
Population: participants with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attack1 Anakinra vs placebo | RR 0.76 [0.54, 1.07] | 1 study · 25 participants | Moderate Downgraded: imprecision |
Duration of attacks Anakinra vs placebo | no estimate extracted | NR | No studies |
Number of days between attacks Anakinra vs placebo | no estimate extracted | NR | No studies |
Prevention of AA amyloidosis Anakinra vs placebo | no estimate extracted | NR | No studies |
Adverse drug reactions Anakinra vs placebo | RR 0.54 [0.12, 2.44] | 1 study · 25 participants | Moderate Downgraded: imprecision |
Acute phase response Anakinra vs placebo | no estimate extracted | 1 study · 20 participants | Moderate Downgraded: imprecision |
Colchicine single dose versus divided dose for reducing inflammation in familial Mediterranean fever
Population: pediatric participants with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attack Colchicine single dose vs divided dose | no estimate extracted | NR | No studies |
Duration of attacks1 Colchicine single dose vs divided dose | no estimate extracted | 1 study · 79 participants | Moderate Downgraded: risk of bias, imprecision |
Number of days between attacks Colchicine single dose vs divided dose | no estimate extracted | NR | No studies |
Prevention of AA amyloidosis Colchicine single dose vs divided dose | no estimate extracted | NR | No studies |
Adverse drug reactions Colchicine single dose vs divided dose | no estimate extracted | 1 study · 79 participants | Moderate Downgraded: risk of bias, imprecision |
Acute phase response Colchicine single dose vs divided dose | no estimate extracted | 1 study · 39 participants | Low Downgraded: risk of bias, imprecision |
Colchicine versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attack ‐ colchicine 0.6 mg orally three times daily Attack1 Colchicine vs placebo | RR 0.21 [0.05, 0.95] | 1 study · 10 participants | Low Downgraded: risk of bias |
Number of participants experiencing an attack ‐ colchicine 0.5 mg orally two times daily Attack8 Colchicine vs placebo | RR 0.78 [0.49, 1.23] | 1 study · 20 participants | Low Downgraded: risk of bias |
Rilonacept versus placebo for reducing inflammation in familial Mediterranean fever
Population: people with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing an attack Attack1 Rilonacept vs placebo | RR 0.87 [0.59, 1.26] | 1 study · 14 participants | Moderate Downgraded: imprecision |
ImmunoGuardTM versus placebo for reducing inflammation in familial Mediterranean fever
Population: participants with familial Mediterranean fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acute phase response ‐ CRP ImmunoGuardTM vs placebo | no estimate extracted | 1 study · 23 participants | Moderate Downgraded: imprecision |
Acute phase response ‐ WBC ImmunoGuardTM vs placebo | no estimate extracted | 1 study · 23 participants | Moderate Downgraded: imprecision |
Acute phase response ‐ ESR ImmunoGuardTM vs placebo | no estimate extracted | 1 study · 23 participants | Moderate Downgraded: imprecision |